We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+3.85%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.11B
AUM Growth
+$28.3M
Cap. Flow
+$26.6M
Cap. Flow %
0.86%
Top 10 Hldgs %
33.83%
Holding
206
New
17
Increased
43
Reduced
39
Closed
34

Top Buys

Rank Stock Value
1
RLYB icon
Rallybio
RLYB
+$33.8M
2
IDXX icon
Idexx Laboratories
IDXX
+$30.1M
3
GH icon
Guardant Health
GH
+$27.2M
4
AMGN icon
Amgen
AMGN
+$25.7M
5
AZN icon
AstraZeneca
AZN
+$21.2M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$35.4M
2
RMD icon
ResMed
RMD
+$33.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.9M
4
DXCM icon
DexCom
DXCM
+$20.1M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$12.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.51%
2 Real Estate 2.72%
3 Industrials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDTX icon
151
Black Diamond Therapeutics
BDTX
$96.8M
$1.12M 0.04%
131,990
– –
MOR
152
DELISTED
MorphoSys AG American Depositary Shares
MOR
$963K 0.03%
81,867
– –
BOLT icon
153
Bolt Biotherapeutics
BOLT
$7.46M
$823K 0.03%
+3,251
New +$919K
NKTX icon
154
Nkarta
NKTX
$149M
$806K 0.03%
28,988
– –
ICPT
155
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$773K 0.02%
52,067
-25,000
-32% -$400K
DTIL icon
156
Precision BioSciences
DTIL
$180M
$727K 0.02%
2,100
– –
ARDX icon
157
Ardelyx
ARDX
$1.22B
$712K 0.02%
539,408
– –
CHCT
158
Community Healthcare Trust
CHCT
$529M
$673K 0.02%
14,900
– –
ONEM
159
DELISTED
1Life Healthcare
ONEM
$633K 0.02%
31,266
– –
UHT
160
Universal Health Realty Income Trust
UHT
$594M
$622K 0.02%
11,258
– –
NHI icon
161
National Health Investors
NHI
$3.69B
$537K 0.02%
10,038
– –
ALXO icon
162
ALX Oncology
ALXO
$266M
$524K 0.02%
+7,099
New +$473K
GMDA
163
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$463K 0.01%
118,142
– –
CRBP icon
164
Corbus Pharmaceuticals
CRBP
$165M
$422K 0.01%
13,783
– –
ASRT
165
DELISTED
Assertio
ASRT
$372K 0.01%
27,372
– –
FUSN
166
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$344K 0.01%
+43,394
New +$365K
SPPI
167
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$250K 0.01%
114,670
– –
YARW
168
Yarrow Bioscience, Inc. Common Stock
YARW
$23.5M
$188K 0.01%
150
– –
OGN icon
169
Organon & Co
OGN
$3.56B
$122K ﹤0.01%
3,717
-50,452
-93% -$1.61M
ALR
170
DELISTED
AlerisLife Inc
ALR
$106K ﹤0.01%
24,237
– –
ORKA
171
Oruka Therapeutics
ORKA
$5.62B
$96K ﹤0.01%
2,705
– –
BLCM
172
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$18K ﹤0.01%
6,000
– –
ACAD icon
173
Acadia Pharmaceuticals
ACAD
$4.37B
– –
-331,789
Closed -$8.09M
ALLK
174
DELISTED
Allakos
ALLK
– –
-133,045
Closed -$11.4M
AMED
175
DELISTED
Amedisys
AMED
– –
-48,070
Closed -$11.8M
5 6
7
8 9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Tekla Capital Management held 206 positions worth $3.11B, up 0.92% from $3.08B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Tekla Capital Management's Q3 2021 filing shows 17 new, 43 increased, 39 reduced and 34 closed positions. Its largest new stake was Rallybio: 288,584 shares worth $37.6M. The largest sale was Elevance Health, an estimated $35.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q3 2021 buy was Rallybio: 288,584 shares worth $37.6M.
  • Tekla Capital Management added most to Idexx Laboratories in Q3 2021, an estimated $30.1M increase.
  • Tekla Capital Management's biggest Q3 2021 reduction was Elevance Health, cutting an estimated $35.4M.
  • Tekla Capital Management fully exited Iovance Biotherapeutics in Q3 2021, selling an estimated $12.2M.
  • Tekla Capital Management's ten largest holdings make up 34% of its $3.11B portfolio in Q3 2021.
  • Tekla Capital Management opened 17 new positions and closed 34 in Q3 2021.
  • Tekla Capital Management's portfolio value rose 0.92% quarter-over-quarter to $3.11B.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.